Association of Admission Dyskalemias With In‐Hospital Mortality in Patients Hospitalized for Heart Failure: Insights From the AMERICCAASS Registry
Clinical Cardiology · 2026-11 · 49 (11)
DOI: 10.1002/clc.70517 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Cardiology, online erschienen am 17.11.2026. Verfasst von Sebastián Seni‐Molina und 24 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Heart failure (HF) is a major global health concern, and dyskalemias are common and associated with adverse outcomes. However, evidence from the Americas, particularly Latin America and the Caribbean, remains limited.
Objective
To evaluate the association between admission dyskalemias and in‐hospital mortality in hospitalized patients with HF across the Americas.
Methods
This subanalysis of the AMERICCAASS Registry included hospitalized patients with HF with available admission serum potassium and documented discharge status. Patients were classified as hypokalemic (< 3.5 mmol/L), normokalemic (3.5–4.9 mmol/L), or hyperkalemic (≥ 5.0 mmol/L). In‐hospital mortality was assessed using Poisson regression and propensity score overlap weighting.
Results
Among 1541 patients, 12.5% had hypokalemia, 75.6% normokalemia, and 11.9% hyperkalemia. Median age was 68 years, and 60.6% were male. Chronic kidney disease was more frequent in hyperkalemia (30.4%), whereas atrial fibrillation was more frequent in hypokalemia (30.7%). Dyskalemic patients more often presented with hypoperfusion profiles and higher New York Heart Association class. In the propensity score overlap‐weighted analysis, hyperkalemia was associated with higher in‐hospital mortality (aRR 1.81; 95% CI 1.10–2.97; p = 0.019), whereas no statistically significant association was detected for hypokalemia (aRR 1.43; 95% CI 0.79–2.60; p = 0.237).
Conclusion
Admission hyperkalemia was associated with higher in‐hospital mortality among hospitalized patients with HF across the Americas. Given the observational design, hyperkalemia should be interpreted primarily as a marker of greater disease severity and short‐term clinical vulnerability rather than as a direct causal determinant of mortality.
Förderung
- AstraZeneca
Zitieren
APA
Seni‐Molina, S., Peláez‐Martinez, J. D., López, J., Morales‐Arias, V., Gutiérrez‐Posso, J. M., Valencia‐Orozco, A., León‐Giraldo, H. O., Rengifo, M. M. B., Toquica, A. R., Silgado, G. A. M., Azcona, D. C., Pérez, M. C. C., Domínguez, Y. H., Vergara, S. G., Fuentes, M. A. G., Bermúdez, L., Hernández, J. E. S., Romero‐Guerra, A., Perna, E. R., …, & Gómez‐Mesa, J. E. (2026). Association of Admission Dyskalemias With In‐Hospital Mortality in Patients Hospitalized for Heart Failure: Insights From the AMERICCAASS Registry. Clinical Cardiology, 49(11). https://doi.org/10.1002/clc.70517
Vancouver
Seni‐Molina S, Peláez‐Martinez JD, López J, Morales‐Arias V, Gutiérrez‐Posso JM, Valencia‐Orozco A, et al. Association of Admission Dyskalemias With In‐Hospital Mortality in Patients Hospitalized for Heart Failure: Insights From the AMERICCAASS Registry. Clinical Cardiology. 2026;49(11). doi:10.1002/clc.70517
BibTeX
@article{SeniMolina2026,
author = {Seni‐Molina, Sebastián and Peláez‐Martinez, Juan David and López, Jhon and Morales‐Arias, Valentina and Gutiérrez‐Posso, Juliana María and Valencia‐Orozco, Andrea and León‐Giraldo, Hoover O. and Rengifo, Mario Miguel Barbosa and Toquica, Alex Rivera and Silgado, Gustavo Adolfo Moreno and Azcona, Domingo Cesar and Pérez, Migdalia Cristina Cóbas and Domínguez, Yilian Herrera and Vergara, Sergio Gabriel and Fuentes, Maite Alexandra González and Bermúdez, Leonardo and Hernández, Jesús Eduardo Sánchez and Romero‐Guerra, Alexander and Perna, Eduardo R. and Rossel, Víctor and Quesada‐Chaves, Daniel and Speranza, Mario and Drazner, Mark H. and Alarco, Walter and Gómez‐Mesa, Juan Esteban},
title = {Association of Admission Dyskalemias With In‐Hospital Mortality in Patients Hospitalized for Heart Failure: Insights From the AMERICCAASS Registry},
journal = {Clinical Cardiology},
year = {2026},
volume = {49},
number = {11},
doi = {10.1002/clc.70517}
}
EUVIMED